PMID- 19087570
OWN - NLM
STAT- MEDLINE
DCOM- 20111128
LR  - 20221207
IS  - 0529-567X (Print)
IS  - 0529-567X (Linking)
VI  - 43
IP  - 11
DP  - 2008 Nov
TI  - [Evaluation of genomic amplification of the human telomerase RNA component gene 
      in the screening of cervical lesions].
PG  - 849-53
AB  - OBJECTIVE: To investigate the genomic amplification of the human telomerase RNA 
      component (hTERC) gene in cervical cytology and evaluate its role in screening of 
      cervical lesions. METHODS: A total of 301 cases were recruited, with liquid-based 
      cytology diagnoses as normal (n = 203), atypical squamous cells (ASC, n = 66), 
      low-grade squamous intraepithelial lesions (LSIL, n = 18), and high-grade 
      squamous intraepithelial lesions (HSIL, n = 14). Following cytological 
      examination, the slides were analyzed using a two-color fluorescence in situ 
      hybridization (FISH) probe targeted to chromosome 3q26 containing hTERC. The 
      hTERC findings were compared to the cytologic and histologic results, as well as 
      high-risk human papilloma viruses (HPV) results. RESULTS: Genomic amplification 
      of hTERC was found in 3.0% (6/203) of normal specimens, 21.2% (14/66) of ASC, 
      44.4% (8/18) of LSIL and 92.9% (13/14) of HSIL, with a significant difference in 
      each pair wise (all P < 0.05). Significantly more cells with 3q26 gain were found 
      in cervical intraepithelial lesion (CIN)II than in CINI (75.0% vs. 20.0%), as 
      well as in CINIII (86.7% vs. 20.0%) and squamous cervical cancer (SCC) than in 
      CINI (100.0% vs. 20.0%)(all P < 0.01). The sensitivity of hTERC amplification was 
      significantly higher than cytological screening (82.6% vs. 17.4%, P < 0.01), and 
      its specificity was higher than high-risk HPV test (67.8% - 73.5% vs. 25.6% - 
      27.7%, P < 0.01) in the diagnosis of HSIL (CINII - III). The abnormal hTERC 
      signal type mostly was 2:3 in CINI (84.9%); whereas in CINII - III, 2:3, 2:4 and 
      4:4 accounted for 44.6%, 24.8% and 17.8%, respectively. CONCLUSION: Testing the 
      gain of chromosome 3q26 in cytological specimens using specific probe for hTERC 
      is powerful in screening of HSIL, and the amplification patterns of 2:4 and 4:4 
      may serve as potential prognosis markers.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Obstetrics and Gynecology, Peking University People's Hospital, 
      Beijing 100044, China.
FAU - Tu, Zheng
AU  - Tu Z
FAU - Zhang, Guo
AU  - Zhang G
FAU - Li, Jing-Ran
AU  - Li JR
FAU - Zhao, Li-Jun
AU  - Zhao LJ
FAU - Zhao, Chao
AU  - Zhao C
FAU - Cui, Shu-Hui
AU  - Cui SH
FAU - Li, Xiao-Ping
AU  - Li XP
FAU - Chen, Zhong
AU  - Chen Z
FAU - Wei, Li-Hui
AU  - Wei LH
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Fu Chan Ke Za Zhi
JT  - Zhonghua fu chan ke za zhi
JID - 16210370R
RN  - 0 (DNA, Viral)
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - DNA, Viral/analysis
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Mass Screening/methods
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Papillomaviridae/genetics
MH  - RNA/*genetics
MH  - Sensitivity and Specificity
MH  - Telomerase/*genetics
MH  - Uterine Cervical Diseases/diagnosis/genetics/pathology
MH  - Uterine Cervical Neoplasms/*diagnosis/genetics/pathology
MH  - Vaginal Smears
MH  - Young Adult
MH  - Uterine Cervical Dysplasia/*diagnosis/genetics/pathology
EDAT- 2008/12/18 09:00
MHDA- 2011/12/13 00:00
CRDT- 2008/12/18 09:00
PHST- 2008/12/18 09:00 [entrez]
PHST- 2008/12/18 09:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PST - ppublish
SO  - Zhonghua Fu Chan Ke Za Zhi. 2008 Nov;43(11):849-53.